30 Leaders of the Healthcare industry

Founded in 2013, the Saudi Public Health Authority is tasked with safeguarding the health and well-being of citizens by enhancing public health protection, preventing diseases, and strengthening preparedness for health emergencies through coordinated efforts among relevant authorities. Since March 2021, the organization has been led by Dr. Abdullah Algwizani, a seasoned expert in internal medicine. Dr. Algwizani earned his Doctor of Internal Medicine Degree from King Saud University in 2007 and further refined his expertise at the University of Iowa from 2015 to 2016. He also served as the Director of the Infection Prevention and Control Department at the Prince Mohammed bin Abdulaziz Hospital in Riyadh from 2016 to 2017.

Throughout his career, Dr. Algwizani has worked closely with various health organizations and ministries to improve and protect public health across the kingdom. As healthcare is a cornerstone of Saudi Arabia’s Vision 2030, the kingdom is committed to a transformative overhaul of its healthcare system. This includes modernizing infrastructure, adopting digital health solutions, empowering the workforce, launching innovative public health initiatives, and improving both the quality of care and patient safety.

And with the government allocating $69 billion to the health and social development sector in 2025, the ministry and Saudi Public Health Authority will be racing against the clock to make sure all residents are in the pink of health.

With its visionary leadership and progressive initiatives, the UAE has become a global magnet for expatriates. This is reflected in the nation’s rise to 22nd place in the 2024 World Happiness Report, up from 26th the previous year. Healthcare is a key driver of this achievement, with the Ministry of Health and Prevention (MOHAP) playing a pivotal role in enhancing the nation’s well-being.

H.E. Minister Abdul Rahman Al Owais has been a prominent figure in the UAE federal government since 2006, when he was appointed minister of Culture, Youth, and Community Development. He also served as acting minister of Health from 2011 to 2013, before being formally appointed minister of Health.

In addition to his ministerial duties, H.E. Al Owais has been a board member of the Sultan Bin Ali Al Owais Cultural Foundation since 1992 and serves as the first vice president of the UAE National Olympic Committee. He earned his Bachelor’s Degree in Accounting and Information Systems from the United Arab Emirates University (UAEU) in 1989.

The ministry was also recognized for its innovative initiatives, such as the e-services program, MOHAP app, Artificial Intelligence Centre, and Zero Trust Project. These initiatives are vital to the ministry’s long-term strategy to improve the quality of government services, promote sustainability, and prepare for future digital transformation.

In December, MOHAP engaged in discussions with the Republic of Serbia to explore opportunities for strengthening collaboration in the healthcare sector. The focus was on enhancing cooperation, exchanging healthcare solutions, and fostering improved communication between health institutions in both countries.

Founded in 1977 in Austin, Texas, Oracle has been a global leader in advancing modern data management and intelligence solutions, providing critical support to the healthcare industry. Holding the reins in its MEA operations since 2022 is Lebanese national Akram Sami Dhaini, bringing with him more than two decades of solid experience in the IT and healthcare sector.

In 2023, Dhaini spearheaded Oracle Health’s $34 million agreement with Burjeel Holdings to implement a groundbreaking Oracle Health EMR solution. This initiative positioned the Abu Dhabi-based healthcare provider as one of the first in the industry to adopt the cutting-edge technology, enhancing its operational capabilities.

“We are working globally to empower hospitals and healthcare systems with digital, open, and interconnected technologies, helping them tackle some of their most complex challenges,” Dhaini stated during the event.

Last year, Oracle was honored with the Best in KLAS award for acute care EMR (Electronic Medical Records) in the MEA region for the sixth consecutive year. The recognition underscores Oracle Health’s ongoing commitment to exceptional customer engagement, driven by strategic partnerships and dedicated, high-touch efforts across the region.

Oracle is creating an open and interconnected healthcare ecosystem, equipped with intelligent tools designed to modernize healthcare and enhance patient outcomes, and its partnership with organizations in the region will pave the way for the industry’s digital transformation.

As one of the few women in a male-dominated industry, Alisha Moopen is a testament that diligence and dynamism go a long way. She is responsible for guiding the strategic direction and growth of the company, with a key focus on leading the expansion of the group into new markets. She is passionate about advancing women’s empowerment and mental health. A strong advocate for workforce diversity, she is committed to breaking down the glass ceiling that women face in the workplace.

In September 2024, Aster DM Healthcare is reportedly focusing on expanding its presence in Saudi Arabia. The company plans to invest $250 million to grow its footprint, with plans to add over 1,000 hospital beds, 180 pharmacies, and 24 medical centers across the kingdom in the coming years.

Just last year, Aster Health Academy, a division of Aster DM Healthcare, announced strategic partnerships with several hospitals across India. These partnerships play a key role in the academy’s curriculum, especially for clinical programs such as Fellowships in emergency medicine, diabetes, and critical care.

Listed on the Bombay Stock Exchange, Aster’s market capitalization is around $3.05 billion and employs 19,502 staff.

The Dubai Health Authority (DHA) is responsible for the comprehensive regulation and governance of the healthcare sector within the emirate of Dubai. Leading the department is Awadh Seghayer Al Ketbi, who was appointed in 2021 and is tasked to oversee and manage the healthcare sector, health insurance, investment, and health tourism services in the emirate. He has held many senior leadership roles in Dubai and has unparalleled management experience spanning almost three decades. Al Ketbi holds a Bachelor’s Degree in Business Administration from Schiller International University in the UK.

Under his watch, the DHA earned three prestigious awards for its groundbreaking “Ejada Ai” value-based healthcare initiative in June, further solidifying the department’s steadfast dedication to achieving global healthcare excellence.

Powered entirely by artificial intelligence (AI), the system aims to enhance preventive care for chronic diseases while improving overall healthcare outcomes and quality of life of patients. The initiative also supports the transition of the health sector from a volume-based to a value-based care model. With its adoption of innovative technology, the authority’s innovative approach to value-based healthcare has been widely recognized, earning multiple accolades, including the UAE Innovates 2024 Award for the Most Innovative Disruptive Project.

As a testament to the department’s unwavering drive for excellence, the DHA’s Network & Analysis Backbone for Integrated Dubai Health (NABIDH) initiative achieved a major milestone in November, integrating over 9.47 million patient records and linking more than 1,300 healthcare facilities across the emirate.

With over 100 years of experience serving patients and healthcare providers, GE HealthCare is pioneering personalized, connected, and compassionate care, while streamlining the patient journey across the entire care pathway. GE HealthCare operates in four business segments – Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

In October, GE HealthCare unveiled a multi-modality partnership with Saudi-based Hayat National Hospitals. This collaboration represents a significant investment in healthcare infrastructure and equipment throughout the kingdom, leveraging on GE’s innovative solutions.

At the 2024 Global Health Exhibition in Riyadh, Sulaiman Al Habib Medical Services Group (HMG), a prominent healthcare provider in the region, announced its investment in advanced radiology innovations from GE HealthCare. This partnership aims to offer patients access to the latest diagnostic and interventional radiology services, promote healthcare equity, and contribute to the kingdom’s Vision 2030 healthcare transformation objectives.

As the head of GE HealthCare International, Elie Chaillot leads the $8 billion entity with a team of 25,000 colleagues that provides healthcare technologies, services and solutions to enable better patient care in more than 160 countries across the globe. “Advances in technology have transformed how we provide and receive medical care today,” he said in an interview with a leading daily.

He was right; according to a report by Black Book Research, the healthcare IT market in the Middle East is projected to grow at a CAGR of 9.2 percent, reaching $7.9 billion by 2028. Leading players such as GE HealthCare International will capitalize on the region’s huge opportunity.

Elif Aral’s journey with Pfizer began in 1995, and since then has achieved significant milestones over the years. Most recently, she spearheaded Pfizer’s An Accord for a Healthier World initiative, where she worked with cross-functional teams to provide Pfizer’s medicines and vaccines on a not-for-profit basis in 45 lower-income countries. This initiative is designed to reduce health disparities by ensuring affordable access to essential medications and tackling systemic barriers to healthcare access.

Before leading the Accord initiative, Aral served as the CV Metabolic and Global Brands lead in Internal Medicine, overseeing a portfolio of over 200 medicines and collaborating globally to enhance performance and ensure critical medications reached patients. She also led Pfizer’s Vaccines Division for Emerging Markets, managing a portfolio worth $1.4 billion. Aral holds a degree in Economics from Istanbul University and has completed executive education programs at prestigious institutions such as Harvard Business School, Wharton, Kellogg Executive Education, and the Management Center of Europe.

In 2023, Pfizer made a significant impact, reaching over 45 million patients and successfully launching 32 products across the Middle East, Russia, and Africa (MERA). The US pharmaceutical giant also extended its reach to approximately 15,000 patients through 30 patient access programs across 11 countries in the region. Additionally, Pfizer’s industry advancements through government partnerships were widely recognized. Key collaborations included the partnership with Haya Karima in Egypt, initiatives with Morocco’s Ministry of Health to achieve universal health coverage (UHC) and improve antimicrobial resistance (AMR), and a partnership with the Department of Health in Abu Dhabi to advance research by generating and analyzing real-world data, focusing on rare diseases such as Sickle Cell Disease.

Saudi Arabia has made healthcare a central focus of its national priorities, committing a substantial $65 billion investment in the kingdom’s healthcare infrastructure. This investment represents 60 percent of the total healthcare spending across all Gulf Cooperation Council (GCC) countries.

As such, the Ministry of Health is spearheading the kingdom’s drive to modernize all aspects of healthcare, including all hospitals and healthcare centers nationwide.

Al Jalajel is currently leading the ministry’s transformation plan and has managed numerous key initiatives throughout his career at several prominent organizations, including the General Authority for Investment (now the Ministry of Investment), the Ministry of Commerce and Industry, and the Ministry of Health. Notably, he has played a significant role in the development of strategies, planning, and overall sector development.

Al Jalajel’s academic background include a Bachelor’s Degree in Computer Science from King Saud University in Riyadh, followed by a Master’s Degree in Computer Science from St. Joseph’s University in Pennsylvania, and an Executive Certificate in Leadership and Management from the Sloan School of Management at MIT.

In December, the minister met Lei Haichao, China’s Minister of the National Health Commission (NHC), during his official visit to the People’s Republic of China. The discussion centered on potential collaborations in the healthcare sector, with a focus on joint efforts to tackle health challenges and utilize shared expertise to improve the quality of healthcare services in the kingdom.

The Health Sector Transformation Program, a key component of the kingdom’s Vision 2030, has unveiled significant milestones achieved in 2024, marking a high point in Saudi Arabia’s healthcare evolution.

Notable achievements were the result of the integration of technology to enhance health services. The “Sehhaty” platform facilitated over 51 million instant and virtual consultation appointments, while more than 30 million beneficiaries were connected to the unified health record system. Additionally, the “Wasfaty” platform served over 14 million individuals, generating more than 40 million prescriptions by the end of last year. These accomplishments highlight the program’s success in improving healthcare access and delivery across the kingdom.

With all these, the ministry’s message is clear: To achieve an integrated and sustainable public health system and disease prevention, build competencies of healthcare industry workers, support innovation, and contribute to the government’s Vision 2030 plans.

KFMC is one of the largest and fastest-growing medical complexes in the kingdom with a total capacity of 1,200 beds.

The $612.75 million state-of-the-art medical facility consists of four hospitals and is expected to treat over 50,000 inpatients and more than 600,000 outpatients annually. With highly qualified and efficient staff and management team, the center seeks to achieve one goal: making KFMC a benchmark in medical care, to which all patients from all over the region are provided with world-class care.

At the helm is Al Ghofaili, who maintains his clinical work as a cardiothoracic surgeon at the center since 2005. He earned his Executive Master’s Degree in Public Health Administration from the University of Minnesota in 2014.

Earlier in his career, he was a fellow at the European Society of Cardiology and completed two fellowships at the University of Ottawa – one in cardiac surgery specializing in transplantation and devices in 2002, and another in thoracic surgery in 2003. He also completed his residency in cardiac surgery at the same university in 2001.

The hospital has also been recognized for its groundbreaking medical achievements, including the use of the Cryoablation technique for tumor removal, intrauterine tumor removal, and the establishment of an advanced cancer and radiation center, as well as a specialized interventional radiology unit.

Just last year, KFMC was named Saudi Arabia’s Hospital of the Year at the Healthcare Asia Awards, where it was recognized for three of its recent healthcare innovations.

The Bahrain Defence Force – Royal Medical Services (BDF-RMS) began in 1968 as a small clinic. By 1979, it had evolved into a 120-bed hospital. Since then, BDF-RMS has steadily grown, expanding its services and facilities to become the second-largest hospital in Bahrain, with a current capacity of 481 beds. While honoring its rich history, BDF-RMS remains committed to continuous improvement, striving to provide the highest quality healthcare. The BDF-RMS is comprised of three main components: The Military Hospital, the Mohammed Bin Khalifa Bin Salman Al Khalifa Cardiac Center (MKCC) and the Field Military Battalion.

Brigadier Dr. Fahad Khalifa Al Khalifa, the commander of Royal Medical Services, is also the chairman of Bahrain’s Overseas Treatment Committee, chairman of the AO Foundation for Bahrain, and a professor at the Royal College of Surgeons in Ireland – Medical University of Bahrain.

A highly experienced surgeon, Brigadier Al Khalifa specializes in sports and complex trauma, upper and lower extremity surgery, joint arthroplasty, degenerative joint diseases, and deformity correction. He holds both Bachelor of Medicine, and Bachelor of Surgery and is a Fellow of The Royal College of Physicians of Canada.

Among the notable achievements of the BDF-RMS took place in November when its medical team successfully carried out a TMJ replacement surgery, a groundbreaking procedure in the Middle East and one of only eight performed worldwide. The surgery restored natural jaw function for a young patient who had experienced breathing difficulties and jaw misalignment resulting from a childhood injury.

Dr. George Pascal Haber, PhD, is the CEO of Cleveland Clinic Abu Dhabi and a staff physician in the Urology Department at the Surgical Subspecialties Institute.

Before joining Cleveland Clinic Abu Dhabi, Dr. Haber was among the experts at the Department of Urology at the Glickman Urological Institute, Cleveland Clinic, Ohio, US. He is also a professor of Surgery (Urology) at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University.

Dr. Haber completed executive education programs at both Wharton and Harvard Business Schools, in addition to earning his medical and doctoral degrees in France.

Since assuming leadership at Cleveland Clinic Abu Dhabi, Dr. Haber has significantly expanded the hospital’s urology patient services, doubling the number of patients treated. He has also prioritized safety, reducing the rate of major complications by 40 percent and cutting the length of stay for high-complexity patients by 50 percent.

As a professor of Surgery and chairman of Urology, Dr. Haber has helped build Cleveland Clinic’s global presence by performing surgeries and serving as a visiting professor in over a dozen countries.

For the second consecutive year, Cleveland Clinic Abu Dhabi, under the M42 group umbrella, has been named the top health research hospital in the UAE by the National Center for Health Research at the Ministry of Health and Prevention (MOHAP). This esteemed recognition highlights the hospital’s pioneering clinical innovations and reinforces its leadership in advancing medical research and education in the UAE and the wider region.

The hospital is currently conducting three genome-based studies focused on liver health, breast health, and obesity, aiming to enhance the health of the Emirati population. These studies leverage DNA to accelerate the development of new treatments and personalized healthcare solutions.

Cleveland Clinic Abu Dhabi has consistently led healthcare innovation in the UAE and the broader region, achieving several pioneering milestones. The hospital has earned a prestigious 5 Diamond Rating for Quality from the Department of Health – Abu Dhabi, reflecting its commitment to exceptional care standards. It introduced the world’s first modified branch-first surgical technique and became the first hospital in the region to receive the Emergency Nurses Association Lantern Award. Additionally, it is the UAE’s first Magnet-accredited hospital and the site of the region’s first complex multi-organ transplant.

The hospital has also set several national and regional firsts, including the UAE’s first accredited Lung Cancer Screening Program, the Middle East’s first fully awake anesthesia for brain tumor surgery, and the region’s first comprehensive Lifestyle Medicine Program for breast cancer. Among its many breakthroughs are the UAE’s first Dopa-Pump surgery, the first awake ECMO retrieval, and the first tricuspid clip heart procedure. Furthermore, it was the first in the Middle East to perform PreserFlo™ MicroShunt glaucoma surgery and the first in the UAE to offer deep brain stimulation for patients with Parkinson’s disease.

These achievements underline Cleveland Clinic Abu Dhabi’s leadership in advancing medical care and treatment in the region.

Sidra Medicine is a 400-bed, innovative healthcare facility dedicated to delivering world-class tertiary care for women and children in Qatar. With its advanced technology and expert medical team, Sidra Medicine is committed to enhancing the health and well-being of its patients through exceptional, personalized care. More recently, the hospital seeks to expand its clinical trials program to offer access to specialized care, with a focus on rare and complex conditions.

Her Excellency Dr. Hanan Mohamed Al Kuwari has served as Qatar’s minister of Public Health since January 2016 and has been the managing director of Hamad Medical Corporation (HMC) since 2007. She chairs numerous prestigious boards, including the Academic Health System International Advisory Board, the Hamad Healthcare Quality Institute International Advisory Board, and several other committees within the Ministry of Public Health. Additionally, she serves as co-chair of the Joint Advisory Board of Weill Cornell Medicine, vice chair of the Qatar Precision Medicine Institute Board, and holds positions on the Qatar University Board of Regents, Sidra Medicine Board of Governors, and the Board of Directors of the Qatar Foundation for Social Work. She is also a member of Qatar Foundation’s Qatar Research, Development, and Innovation Council.

In recognition of her global contributions, Dr. Al Kuwari was elected as an international member of the US National Academy of Medicine (NAM) in October 2018. Dr. Al Kuwari holds a Bachelor’s and Master’s Degree in Healthcare Management and earned her PhD in Healthcare Management from Brunel University in the UK in 2002.

In 2024, Sidra Medicine provided life-saving care to more than 230 injured children from Gaza, delivering critical medical, surgical, and psychological support. The hospital also made significant strides in gene therapy and precision medicine, while performing the region’s first high-risk cesarean section in an angiography suite. These milestones highlight Sidra Medicine’s commitment to advancing healthcare and supporting patients in critical need.

A key priority for Sidra Medicine this year is to further advance research and innovation, with a particular emphasis on expanding its initiatives in precision medicine, which has long been a core focus of the institution.

M42 is a pioneering global health powerhouse, committed to shaping a sustainable future of healthcare in the Middle East and beyond. Headquartered in Abu Dhabi, the organization is transforming lives with innovative solutions that tackle the world’s most pressing health and diagnostic challenges. By leveraging exceptional medical and data-centric technologies, including genomics and artificial intelligence, M42 is providing the highest level of personalized, precise, and preventative care, disrupting the global healthcare landscape.

With a workforce of over 20,000 employees and more than 450 facilities across 26 countries, M42 was established in 2022 through the merger of G42 Healthcare and Mubadala Health. The company seamlessly integrates advanced health technologies with state-of-the-art healthcare facilities, delivering world-class solutions, services, and care.

Leading the charge is Hasan Jasem Al Nowais, a distinguished business leader and the managing director and Group CEO of M42. Under his visionary leadership, M42 is revolutionizing the healthcare industry by leveraging advanced technologies and leading-edge sequencing, driving a new era of personalized, precise, and preventative care through its expansive global network.

In addition to his role at M42, Al Nowais holds several prominent positions, including chairman of Cleveland Clinic Abu Dhabi, Rosewood Abu Dhabi, and Four Seasons Hotel Abu Dhabi. He also serves as a board member of Yas Holdings and chairman of the Yas Holdings Healthcare Committee.

Before M42, he served as CEO of Mubadala Health, where he played a pivotal role in establishing Mubadala Health as an independent entity. He led the growth and integration of its network of healthcare facilities, focusing on enhancing patient experience, pioneering innovative solutions, fostering sector collaboration, and building strategic global partnerships to improve clinical outcomes.

Earlier in his career, Al Nowais joined Mubadala Investment Company (MIC) in 2007, where he managed international hospitality projects across the US, Middle East, and Asia, working with renowned brands including Viceroy Hotel Group, Four Seasons Hotels and Resorts, and Rosewood Hotels and Resorts

He also served as the chief administrative officer at Cleveland Clinic Abu Dhabi, where he successfully managed operations across various strategic functions within the prestigious hospital.

Al Nowais is a graduate of the American University in Washington, D.C. and holds certifications from Cornell University and Harvard Medical School, among others.

In December, Amana Healthcare, a key part of the M42 group, was honored for the third consecutive year with the prestigious Diamond Award for ‘Safety in Digital Transformation’ by the Arab Hospitals Federation. This recognition highlights Amana’s unwavering commitment to enhancing patient safety through innovative digital advancements.

Building on its success from the previous year’s Silver Star award, Amana Healthcare has continued to demonstrate exceptional leadership in digital safety initiatives. The organization has achieved significant improvements in safety metrics, advanced technology applications, and reinforced data security and patient privacy.

Since its creation in 1816, AXA has become a globally recognized insurance experts present in 51 countries, employing 147,000 staff and with around 94 million customers. Its core focus is protecting not just property, but also health and financial assets. AXA offers a diverse range of products and services, always centered around one key principle: Understanding and meeting the expectations and needs of customers.

In a fast-changing environment, the group is committed to continually reinventing its operations to make insurance simpler and more accessible. The group is also fully dedicated to digital transformation, ensuring that products, advice, and assistance are available through any channel. Beyond overcoming technical challenges, AXA’s vision is to move beyond being just a provider called upon in emergencies. Its goal is to become a trusted partner, present at every significant moment in the lives of policyholders — providing them with the peace of mind they deserve.

As one of the pillars of the group, Hassan El-Shabrawishi leads the insurer’s Africa, Türkiye, Middle East, Latin America, Thailand, Indonesia, Philippines, India operations.

El-Shabrawishi helped AXA establish operations in Egypt from scratch, and later setting up AXA Africa Health. Under his leadership, AXA Egypt went on to become a multi-million-dollar company in just three years, and AXA Africa Health became the largest investor in healthcare in Africa.

On the sustainability front, AXA announced in April the launch of a new training initiative aimed at educating its individual shareholders on the challenges of climate change, further reinforcing its commitment to being a responsible player in addressing environmental issues.

Climate change mitigation, prevention, and adaptation are central to AXA’s strategy as an insurer, investor, and employer. Following the successful completion of climate change training for 96 percent of its employees through AXA Climate’s specialized program, the group is now extending this valuable resource to its individual shareholders with The Climate School.

Developed by AXA Climate, The Climate School is the most comprehensive digital micro-learning platform on environmental and sustainability issues, created with the input of over 120 scientists, experts, and researchers from around the globe. It offers an engaging, science-based learning experience that explains the impacts of climate change on both the environment and businesses, while providing actionable insights on how individuals and companies can reduce their carbon footprint. Through this platform, AXA aims to deepen the understanding and awareness of climate change among its individual shareholders, empowering them to take informed action on these critical issues.

Moreover, AXA has made a strong start to its new strategic plan, Unlock the Future, achieving robust operational performance in the first half of 2024. The group’s net income reached $4.12 billion, marking a 5 percent increase compared to the same period last year.

AXA’s strategy is centered on driving profitable organic growth, enhancing technical excellence across its operations, and fostering operational efficiency throughout the organization. The management team is confident that these efforts position the group to create sustained shareholder value and deliver attractive returns.

Mediclinic Middle East is one of the leading private healthcare providers in the UAE, with a strong presence in Dubai, Abu Dhabi, and Al Ain. The healthcare provider is renowned for its trusted brand and reputation, offering clinical care that meets internationally recognized standards in this rapidly developing region.

The company operates seven hospitals, 28 outpatient clinics, 978 outpatient beds, and employs more than 7,700 dedicated staff members.

South African Hein van Eck leads the organization; he is a seasoned healthcare executive with over 20 years of experience in leadership, strategy, operations, and business growth across both local and international healthcare sectors. Appointed CEO of Mediclinic Middle East in 2023, van Eck previously served as the company’s chief strategy officer. In his current role, he provides strategic leadership, guiding the company’s growth, policy development, budgeting, and ensuring both financial and operational excellence.

Van Eck is a fellow of the Institute and Faculty of Actuaries in the UK (FIA) and the Actuarial Society of South Africa (FASSA). He also holds a BSc from the University of Stellenbosch.

In March 2024, Mediclinic City Hospital made history as the first private hospital in the UAE to receive the prestigious Patient Safety Friendly Hospital Initiative (PSFHI) certification. This achievement followed five days of rigorous audits by the World Health Organization (WHO) and the UAE’s Ministry of Health and Prevention (MOHAP). The PSFHI, launched by WHO in 2011 and managed by MOHAP, aims to promote patient safety practices in healthcare facilities by setting 140 safety standards across key domains.

In November 2024, Mediclinic launched Mediclinic Woman, a specialized health program focusing on women’s health. This platform ensures that women seeking a healthy lifestyle have easy access to comprehensive women’s health services at every stage of life. From adolescence to pregnancy, antenatal care, labor, and delivery, to addressing specific women’s health issues like endometriosis, PCOS, and menopause, Mediclinic Woman offers holistic care that spans screening, fertility treatments, and aesthetic procedures.

Mediclinic’s integrated care pathway for women emphasizes not only treatment for existing conditions but also preventative care, longevity, and overall wellness. The company’s services include vital screenings, such as Pap smears and mammograms, which are crucial for preventing common cancers like cervical and breast cancer.

In the same month, Mediclinic City Hospital celebrated another milestone, completing 1,500 robotic surgeries as part of its advanced robotic surgery program. Utilizing the da Vinci Xi HD 4-arm robotic system, the program combines traditional laparoscopic techniques with precision robotic technology, allowing surgeons to perform minimally invasive procedures with high-definition 3D views of the surgical site, ensuring superior outcomes for patients.

AstraZeneca is a global, science-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of prescription medicines, with a primary focus on three key therapeutic areas: Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Operating in over 100 countries and employing around 90,000 staff, AstraZeneca’s innovative medicines are used by millions of patients worldwide, advancing the fight against serious diseases.

The Near East region, considered a growth market for AstraZeneca, was established in December 2014. This cluster includes Iraq, Iran, Lebanon, Jordan, Libya, Sudan, Syria, and Palestine, each with its own unique business environment. AstraZeneca aims to create sustainable value in these markets, improving access to innovative medicines and driving meaningful healthcare advancements.

By 2017, AstraZeneca had achieved significant success in the Near East, ranking first among multinational and local pharmaceutical companies in Iraq, second in Jordan, and third in Lebanon.

In September 2023, AstraZeneca officially opened its new sustainable offices in Dubai Science Park. This milestone is a significant step in the company’s commitment to reducing its carbon footprint in the UAE. The offices are part of AstraZeneca’s broader initiative to drive the transition to sustainable healthcare in the UAE, aligning with the company’s global Ambition Zero Carbon program. Key initiatives include a plan to switch to electric vehicles (EV100) by 2025 and the launch of its first next-generation inhaler, featuring a near-zero global warming potential propellant, in the UAE market. These efforts reflect AstraZeneca’s dedication to advancing environmental sustainability and healthcare innovation.

On the financial front, AstraZeneca reported robust growth, with total revenue reaching $25.62 billion in the first half of 2024, an 18 percent increase compared to the same period in 2023. This growth was driven by a significant rise in product sales and a continued increase in alliance revenue from partnered medicines. Looking ahead, the company has set an ambitious target to reach $80 billion in total revenue by 2030.

In the area of strategic partnerships, AstraZeneca has made notable progress, including the signing of an MoU with the Department of Health – Abu Dhabi (DoH) at the BIO International Convention 2024. This partnership aims to establish a world-class Rare Diseases Centre of Excellence in Abu Dhabi. By leveraging the emirate’s advanced healthcare infrastructure and AstraZeneca’s global expertise in rare diseases, the collaboration seeks to improve the lives of those impacted by rare conditions, both regionally and globally.

In the Middle East, AstraZeneca is led by Iskra Reic, who was appointed executive vice-president, International, in December 2024. Reic is responsible for overseeing strategy and driving sustainable growth across the international region, which includes China, Asia, Eurasia, the Middle East and Africa, Latin America, and Australia and New Zealand.

Reic previously served as EVP of Vaccines & Immune Therapies, where she oversaw both early- and late-stage development of the unit’s pipeline, including COVID-19 and RSV vaccines, monoclonal antibodies, strategic partnerships, acquisitions, and commercial operations. She has been part of AstraZeneca’s senior executive team since 2017 and has held senior leadership roles across Central and Eastern Europe, the Middle East, Africa, and Eurasia.

Reic holds a PhD in Strategy and Leadership, as well as an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management in Slovenia. Additionally, she holds a Doctor of Dental Medicine (DMD) degree from the Medical University of Zagreb.

In addition to her role at AstraZeneca, Reic was appointed a non-executive director of the Board of Directors of myTomorrows in July 2024. She is also a member of the Steering Committee of the Partnership for Health System Sustainability and Resilience.

Cigna Middle East is a key regional arm of Cigna Corporation, a global health services company with roots in the United States, serving over 180 million customers worldwide. Cigna Middle East operates across the GCC markets and Lebanon through locally regulated entities and strategic partner arrangements.

With more than 60 years of global experience and over 20 years in the Middle East, Cigna’s health insurance plans are meticulously crafted to provide quality, affordable healthcare solutions tailored to the diverse needs of its customers. The company offers both health and wellness services to individuals, businesses, and government entities across the region and beyond.

Cigna’s mission is centered around delivering high-quality care that not only addresses health concerns but also focuses on improving resilience, reducing stress, and supporting emotional health. The company strives to empower individuals with the tools they need to better manage their health and well-being.

Leading Cigna’s regional operations is Leah Cotterill, whose responsibilities include enhancing access to top-tier health and wellness services while driving strategic growth across the Middle East and Africa. With over 25 years of experience in the health and wellness sector, Cotterill is a proven leader dedicated to making a meaningful impact.

Before assuming her current role, Cotterill served as chief distribution officer for Cigna Healthcare MEA, leading market growth teams across the Middle East and Africa. She collaborated closely with these teams to craft market strategies and address the needs of buyer groups. Additionally, she oversaw the region’s Individual Private Medical Insurance (IPMI) business unit.

Earlier in her career, Cotterill was the chief operating officer for Cigna Healthcare MEA, where she developed a customer-centric operating model to streamline the execution of the company’s strategic priorities. In 2013, Cotterill took on a key role in the United States, where she led the Client Management Team for Global Health Benefits in North America. She later returned to the Middle East to manage the migration of global clients to Cigna’s new operating model following the acquisition of Zurich Insurance Middle East.

Cotterill’s career spans the Middle East, the United States, and the United Kingdom, giving her a global perspective that allows her to drive success in diverse markets. Known for her energy, resilience, and collaborative spirit, she consistently focuses on achieving growth and delivering exceptional results.

She holds an MBA with distinction from Hult International Business School, earned in 2023. Outside of her professional achievements, Cotterill is passionate about gender equity, diversity, and inclusion. She is also an active advocate for Cigna’s Women in Networking (WIN) initiative.

“At Cigna Healthcare, we are deeply invested in enhancing the health and vitality of the people we serve, while increasing access to quality care. Our products and solutions are designed to provide simple, affordable, and flexible care that cater to the whole health needs of people and empower them to manage their health better. Cigna Healthcare’s diverse portfolio of robust solutions has made it the dedicated “go-to” health insurer for employers, governments, and individuals in the region,” she said on the company website.

In November 2024, the Health Holding Company of the Kingdom of Saudi Arabia (HHC) and Cigna International Corporation signed a Letter of Intent (LOI) to explore a strategic collaboration aimed at advancing healthcare delivery in Saudi Arabia, as part of the Kingdom’s Vision 2030 Health Sector Transformation.

The partnership will focus on supporting the Kingdom’s healthcare clusters in transitioning to a value-based care model, with key objectives including improving patient outcomes, optimizing drug utilization, and exploring opportunities to develop medical tourism. Cigna was chosen for its extensive expertise in health insurance and value-based healthcare, positioning it as an ideal partner to help HHC implement and expand effective healthcare solutions across Saudi Arabia.

On the financial front, Cigna continues its impressive performance, recording $1.9 billion in adjusted income from operations for the second quarter of 2024.

Starting from humble beginnings in 1988 with one hospital in Jeddah, today, Saudi German Health (SGH) manages several standalone clinics, 11 operational facilities, and many more under construction. Today, more than 9,000 doctors, nurses, healthcare professionals, and staff call SGH their home.

With a network of 22 medical facilities and more than 3,000 beds, the organization serves over 2.5 million patients annually across the region. These impressive figures reflect SHG’s commitment to providing high-quality healthcare services and meeting the growing needs of the communities it serves.

In 1998, Saudi German Hospital Jeddah became the first hospital to introduce IT such as electronic medical records and automation in the Middle East healthcare industry; solidifying the company’s unwavering commitment to excellence and innovation.

Makarem Sobhi Batterjee became the president and vice-chairman of Saudi German Health in 2017 and paved the way towards expansion and advancement for our group by broadening its German foundation to build strong collaborations with renowned healthcare providers in the US, Canada, UK, and beyond. Under his leadership, SGH has focused on renovating hospitals, digitally transforming services, enhancing patient experience, introducing unique medical specialties, providing advanced treatments, bringing international doctors to the region, and building partnerships with international medical organizations.

Selected as a member of the prestigious Bretton Woods Committee in Washington D.C., Batterjee has received numerous accolades throughout his career. In 2008, he was honored as a Young Global Leader by the World Economic Forum (WEF) in Davos. The following year, he was chosen as the Middle East Young Entrepreneur of the Year by a panel at the Leaders in Dubai – Middle East Awards. In 2004, he became the founding president of the Entrepreneur Organization (EO) Saudi Chapter. A member of YPO, Batterjee also pioneered the first women’s fitness clubs in Saudi Arabia.

Among the highlights of the organization was the signing of an MoU (Memorandum of Understanding) in 2023 between SGH and the University of Manchester Middle East Centre – marking the university’s first partnership in Saudi Arabia’s healthcare sector.

Saudi German Health has an extensive and growing network of hospitals, clinics, pharmacies and educational facilities across the region providing comprehensive care for millions of patients every year. The university is developing its corporate partnership program in Saudi Arabia, which is already an important source of part-time master’s students for the Middle East Centre and home to a rapidly growing alumni community.

In June, Saudi German hospitals in Riyadh, Aseer and Jeddah earned the International Consortium for Health Outcomes Measurement (ICHOM) accreditation, becoming the first-ever healthcare provider in KSA to achieve the accreditation, marking a milestone in outcome-focused healthcare in the region. The exemplary achievement showcases SGH’s steadfast commitment to delivering outcome-focused and cost-effective healthcare while consolidating its position as a leading provider of value-based healthcare in KSA.

Last year, in another feather in the organization’s cap, SGH received the Superbrand Award as a testament to SGH’s strength, value, and excellence in the healthcare sector. Endorsed by the esteemed UAE Superbrands Council, the recognition enhances the company’s credibility, boosts its global visibility, and reinforces its position as a leading and trusted healthcare provider in the region.

Tadawul-listed SGH (Middle East Healthcare Co) has a market capitalization of $1.84 billion and recorded $46.6 million in profit for the first nine months of 2024.

The Department of Health – Abu Dhabi (DoH) is the regulatory authority overseeing the healthcare sector in the UAE capital. Its mission is to ensure excellence in healthcare delivery, focusing on monitoring the health status of the population and driving improvements across the healthcare system. DoH is tasked with formulating strategies for the health system, analyzing population health data, and evaluating the system’s performance.

In addition to enforcing regulations and standards, DoH encourages the adoption of world-class best practices and performance targets by healthcare providers throughout the emirate. The department also runs programs to promote healthy living standards among Abu Dhabi residents while regulating the scope of services, premiums, and reimbursement rates within the healthcare system.

The DoH is led by H.E. Mansoor Al Mansoori, who also serves as a member of the Abu Dhabi Executive Council. Al Mansoori is a prominent leader with extensive experience across government and private sectors, including telecommunications, energy, and technology. He has a proven track record in strategic planning, institutional development, and performance-based management. As group chief operating officer of G42, Al Mansoori played a pivotal role in the organization’s strategic partnerships, business efficiencies, and innovation. His leadership during the UAE’s national Covid-19 response and his role as chairman of Bayanat during the company’s successful IPO at ADX further highlighted his capabilities.

Prior to G42, Al Mansoori was the director general of the UAE National Media Council, where he led efforts that transformed the council’s operations and earned the Government Excellence Award in 2018. He has held various influential board positions and is currently the chairman of Injazat and Presight, as well as a board member of Etisalat and Multiply Group. Al Mansoori was also a speaker at the 2019 Young World Summit in London and holds a Master’s Degree in Strategic Security Studies and National Resources Management from the UAE National Defense College, along with several leadership certificates from prestigious institutions like MIT and London Business School.

In October 2024, DoH signed a Memorandum of Understanding (MoU) with Accenture, a leading global professional services company, to enhance health data governance, elevate healthcare services, and improve patient outcomes in Abu Dhabi. The collaboration aims to leverage Accenture’s advanced AI and data solutions to propel the emirate’s healthcare sector forward, focusing on data governance execution, health AI use cases, and health data infrastructure. This strategic partnership will further DoH’s mission to build a resilient, data-driven, and innovative healthcare ecosystem.

The DoH’s efforts were further recognized when it received the Startup Ecosystem Stars Award in 2024, highlighting Abu Dhabi’s position as a global leader in healthcare innovation and life sciences. Since 2021, DoH has supported 80 healthcare startups, creating 926 specialized jobs and driving economic growth in the life sciences sector, which has seen a remarkable annual growth rate of 35.8 percent.

With the UAE allocating AED 5.745 billion ($1.56 billion) to healthcare and community disease prevention for the 2025 fiscal year, the DoH, under Al Mansoori’s leadership, continues to advance its mission, managing multiple critical initiatives to ensure the long-term well-being of Abu Dhabi’s residents.

Sheikh Shakhbout Medical City (SSMC), one of the largest hospitals in the UAE and a subsidiary of PureHealth, was established to support the goals of Abu Dhabi’s Economic Vision 2030 and elevate healthcare services within the emirate. The hospital’s state-of-the-art medical facilities align with its vision to position Abu Dhabi as a global healthcare hub.

As an integrated medical facility, SSMC offers patients advanced healthcare services, utilizing cutting-edge technologies and diagnostic tools to provide the highest standard of care. Opened in November 2019 with a total construction cost of $1 billion, SSMC is a cornerstone in the future of healthcare in Abu Dhabi and the wider region, standing as one of the UAE’s largest tertiary hospitals. The hospital is committed to clinical excellence and a superior patient experience.

By 2023, SSMC had managed an impressive annual patient volume, with approximately 600,000 interactions, including over 445,000 outpatient visits, 129,000 emergency cases, and more than 27,000 inpatient admissions. These services are delivered by a team of 500 physicians across 46 specialties, supported by 1,500 skilled nurses.

SSMC’s ongoing achievements were recognized in September 2023, when it was accepted as a Premier Associate Member of the International Hospital Federation. In another significant milestone, the hospital performed Abu Dhabi’s first pulse field ablation procedure for atrial fibrillation in November 2023, successfully treating two complex cases of this heart condition, characterized by a rapid and irregular heartbeat.

CEO Dr. Marwan Al Kaabi, with over 18 years of experience in complex operations and leadership, has been instrumental in driving operational efficiency and enhancing customer care at SSMC. Known for his expertise in enterprise risk management, Dr. Al Kaabi has built a formidable reputation for his leadership in healthcare. Before joining SSMC, he played a crucial role at PureHealth as chief of critical infrastructure management and response, overseeing the planning and implementation of crisis management and ensuring health and safety standards.

Previously, as chief operating officer at Abu Dhabi Health Services Company (SEHA), Dr. Al Kaabi led the organization through numerous strategic initiatives aimed at advancing healthcare delivery. He brings this wealth of experience to SSMC, where his visionary leadership continues to shape its success. Dr. Al Kaabi is also a member of the Advisory Board at the United Arab Emirates University.

Dr. Al Kaabi holds a Master’s Degree in Health Emergency Management from Boston University and an executive certificate in managing healthcare delivery from Harvard Business School, equipping him with a comprehensive understanding of both medical practice and healthcare management.

“Our mission is fueled by a commitment to providing transformational healthcare solutions that foster profound trust and loyalty across the region. We embrace a philosophy centered on ethical practices,” Dr. Al Kaabi said in his message on the company’s website.

Siemens Healthineers is a global leader in medical technology with over 125 years of experience in driving breakthroughs in healthcare. Its extensive portfolio, which spans in vitro and in vivo diagnostics, image-guided therapy, and cancer care, plays a critical role in clinical decision-making and patient treatment.

The company’s strengths are rooted in patient twinning, precision therapy, and the integration of digital technologies, data analytics, and artificial intelligence (AI). With a robust foundation of experience and cutting-edge technology, Siemens Healthineers is well-positioned to tackle some of the most pressing challenges in healthcare. Its ongoing innovation aims to combat the world’s most significant diseases, enhance operational efficiency, and broaden access to healthcare globally.

Employing over 71,000 professionals across more than 70 countries, Siemens Healthineers is at the forefront of healthcare advancement, working tirelessly to improve the lives of millions of patients worldwide.

Ole Per Maloy joined Siemens Healthineers in 2018 as managing director for the Middle East and Africa, based in Dubai. He brings extensive regional and international expertise to his role, where he is responsible for driving growth strategies, fostering relationships with healthcare providers, and expanding the Siemens Healthineers Academy’s educational offerings.

Before his current position, Maloy served as senior vice president and general manager for Siemens Healthineers’ Diagnostic Imaging portfolio in Western Europe and Western Africa, based in London. In this capacity, he managed an annual volume of $1.04 billion and led a team of approximately 1,800 staff.

With over 30 years of experience at Siemens, Maloy is well-equipped to anticipate the needs of the global organization as it continues to expand its presence and impact in healthcare.

In February 2023, Siemens Healthineers strengthened its long-standing partnership with Aster DM Healthcare by signing a Master Research Agreement (MRA) to develop and implement innovative solutions in clinical diagnosis and treatment. This collaboration leverages Siemens Healthineers’ global expertise in R&D and Aster DM Healthcare’s diverse hospital infrastructure and research interests, further expanding the existing Value Partnership between the two organizations.

In its 2024 Sustainability Report, Siemens Healthineers outlined its focus on increasing patient impact, education, and training for the healthcare workforce. The company set an ambitious target to achieve 3.3 billion patient touchpoints by 2030, with 1.25 billion of those occurring in low- and middle-income countries.

On the sustainability front, Siemens Healthineers is committed to achieving Net Zero emissions by 2050. In fiscal year 2024, the company achieved a 40 percent reduction in greenhouse gas emissions from its operations, while also collaborating with suppliers and customers to build a more circular and decarbonized value chain. Additionally, the company met its diversity and external recognition targets for 2025, a year ahead of schedule.

Established in 2010, Response Plus Holding (RPM) is one of the largest providers of onsite healthcare, medical emergency services, and occupational health solutions in the GCC. In September 2021, RPM transitioned to Response Plus Holding PJSC and was listed on the Abu Dhabi Securities Exchange (ADX). It is also a global micro-cap company on the FTSE GEIS. With a fleet of 426 ambulances, RPM boasts the largest medical vehicle fleet in the region and has become a trusted partner of choice for healthcare services. Over the years, RPM has conducted over 1.2 million training sessions for healthcare and non-healthcare professionals, performed more than 10,000 helicopter medical evacuations, and provided emergency medical support for major sporting events across the region.

RPM operates over 360 onsite clinics, supported by a dedicated team of 1,600 healthcare professionals, and plays a vital role in shaping the healthcare sector across MENA. The company has significantly contributed to making the UAE one of the top destinations for medical tourism globally. RPM’s cost-effective healthcare solutions have added value to numerous medical institutions, and its rapid expansion into strategic locations across the UAE, Saudi Arabia, Oman, India, and Ethiopia has positioned RPM as one of the largest medical staffing organizations in the region.

Omran Al Khoori, RPM’s chairman, is a visionary leader who has been instrumental in reshaping the region’s healthcare landscape. As a board member of Burjeel Holdings, Al Khoori has helped elevate the organization into one of the UAE’s leading private healthcare providers. Under his leadership, RPM has forged high-value healthcare partnerships with government entities and industry leaders, while championing Emiratisation initiatives to support the UAE’s nationalization goals.

Al Khoori holds a degree in Business Administration from Suffolk University, Boston, and serves as a board member for Al Maryah Community Bank, Dubai Islamic Insurance & Re-Insurance Company (Aman), and Amanat Holdings. He became a board member of Response Plus Holding upon its ADX listing in 2021. In this enhanced role, Al Khoori has overseen RPM’s strategic initiatives, ensuring the company maintains its market leadership through major partnerships and world-class medical services. He is also driving RPM’s investment strategy, positioning the company for sustained growth and success.

In January 2024, RPM completed the strategic acquisition of UK-based Prometheus Medical, a respected provider of healthcare training and consultancy services. Prometheus is part of the Safeguard Medical umbrella, a global leader in emergency medical technologies and specialized training for first responders.

Financially, RPM has shown significant growth. For the third quarter of 2024, the company reported a 30 percent rise in revenue, reaching AED 323.03 million ($87.95 million), compared to AED 247.82 million ($67.47 million) in the same period in 2023. RPM’s net profit before tax also increased by 15 percent, reaching AED 43.49 million ($11.84 million) compared to AED 37.8 million ($10.29 million) in the third quarter of 2023, demonstrating the company’s robust performance and growth trajectory.

Under the leadership of Shaista Asif, co-founder and group CEO, PureHealth has achieved significant expansion and success. Key milestones include strategic partnerships with Abu Dhabi Health Services Co (SEHA), The National Rehabilitation Center (NRC), and The National Health Insurance Company (Daman), as well as a $490 million investment in US-based Ardent Health Services. Asif also spearheaded the landmark acquisition of Circle Health Group in the UK, a pioneering move by a UAE-based healthcare group, in a deal valued at over AED 4.4 billion ($1.2 billion).

Asif’s leadership has been instrumental in driving the group’s commitment to sustainability. PureHealth is a key participant in the UN-backed Race to Zero initiative for Climate Change, with a target of achieving net-zero emissions by 2040.

A strong advocate for technological innovation, Asif has led the development of several transformative healthcare solutions, including Pura, the region’s first AI-backed healthcare app designed to promote healthier, longer lives, and PureNet, a digital health-as-a-service platform.

Asif is also a passionate advocate for women’s empowerment, having initiated the Remarkable Emirati Women Summit, a platform that recognizes and inspires the achievements of Emirati women.

“At PureHealth, we are working towards adding up to 25 additional years of higher-quality, happier, and healthier living to the UAE’s average life expectancy over the next 50 years,” she said.

With exceptional leadership, PureHealth has maintained impressive financial performance. In the first nine months of 2024, the ADX-listed group reported a 56 percent increase in consolidated revenue, reaching AED 19.0 billion ($5.17 billion), primarily driven by the hospitals segment and supported by both organic growth and successful acquisitions in local and international markets.

The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) totaled AED 3.126 billion ($851 million) in the same period, reflecting a 26 percent year-on-year increase, with an EBITDA margin of 16.5 percent. PureHealth also achieved a net profit of AED 1.4 billion ($381.16 million) in the first nine months of 2024, marking a 13 percent year-on-year growth and a net profit margin of 7.6 percent.

Burjeel Holdings is a leading healthcare provider based in the UAE, offering a comprehensive range of medical services through a network of hospitals, clinics, and specialized healthcare centers. The organization is committed to delivering high-quality, patient-centered care while advancing the healthcare landscape both within the UAE and across the region. Burjeel operates 89 medical assets, including 19 hospitals with 1,730 beds, and employs 1,632 doctors. It is renowned for its expertise across various medical disciplines, such as cardiology, oncology, orthopedics, and neurology. With modern facilities featuring cutting-edge medical equipment and laboratories, Burjeel holds approximately 19% of the UAE’s inpatient market share, serving 6 million patients annually – demonstrating its reputation for world-class healthcare services.

Over the years, ADX-listed Burjeel Holdings has expanded its regional presence, focusing on making healthcare more accessible while investing in advanced medical research and technology. The company is dedicated to improving health outcomes through personalized care and the integration of innovative digital health solutions.

Since its establishment in 2007, Burjeel Holdings has quickly become a leader in healthcare, positioning itself as a premium private healthcare provider in the region. With ambitious plans for growth, the group is set to further extend its healthcare services across the Middle East and beyond.

As chairman and managing director, Dr. Shamsheer Vayalil has been instrumental in leading the group’s remarkable growth, transforming it from a single hospital in 2007 to a comprehensive healthcare provider with a rapidly expanding global footprint. Dr. Shamsheer, who began his career as a radiologist at Sheikh Khalifa Medical City, founded LLH Hospital in 2007, Burjeel’s first facility. He oversees a diverse investment portfolio that includes Burjeel Holdings, RPM, LifePharma, Lakeshore Hospital, Ziva, Keita, and Educare Institute. Under his leadership, the group has become one of the most recognizable and influential organizations in the healthcare industry.

In the realm of corporate social responsibility (CSR), Burjeel has made significant strides, impacting thousands of lives across the MENA region and the Indian subcontinent. Its health screening and awareness programs for the worker community have transformed countless lives, while the group remains one of the first institutions to assist victims of calamities and disasters in both the Middle East and India.

In December, Burjeel Holdings continued to expand its regional presence with the acquisition of a 100 percent stake in the Specialist Physiotherapy Center, a leading healthcare facility in Makkah, through its subsidiary, Burjeel KSA. With an investment of SAR 6.5 million ($1.73 million), this acquisition enhances Burjeel’s ability to provide world-class physiotherapy and rehabilitation services, further supporting its growth strategy in Saudi Arabia.

In January, Burjeel renewed its strategic partnership with Asian Champions Al Ain Football Club for an additional three years, reinforcing its commitment to the well-being of the sports community. Burjeel will continue to serve as one of the club’s key partners until 2027.

Burjeel’s growth trajectory remains strong, with a 14 percent increase in group revenue for the third quarter of 2024, reaching AED 1.3 billion ($353.9 million), driven by increased patient footfall and improved patient yield. The group saw a 12 percent rise in patient footfall in Q3 2024, bringing the total to 4.8 million for the first nine months of the year. Additionally, hospital revenue grew by 13 percent, reaching AED 1.2 billion ($326.7 million), primarily fueled by a 34 percent year-on-year increase in the oncology segment.

“As emerging markets achieve growth, there is a pressing need for them to build sustainable healthcare systems. World-class economies like the UAE need the best health services to cater to populations who potentially face increased lifestyle and wellness issues. In this new landscape, there is an urgent need for affordable and accessible services, without compromising on quality,” he said in an interview with Arab Health.

Medcare is a leading healthcare network based in the UAE and a key venture of Aster DM Healthcare, a global healthcare group with over 317 medical establishments across nine countries, including the GCC, India, and Africa. Committed to delivering high-quality, personalized care, Medcare upholds its core promise of treating patients with exceptional care and respect.

The Medcare network includes four multispecialty hospitals, four specialty centers, and 15 medical centers, supported by a team of more than 350 highly qualified doctors. As part of Aster DM Healthcare, Medcare benefits from the group’s extensive reach, serving over 10 million patients annually across its hospitals, clinics, and pharmacies throughout the Middle East and India.

Medcare is renowned for its patient-centered approach, offering a broad spectrum of medical services through state-of-the-art facilities. It operates several hospitals across the UAE, including its flagship Medcare Hospital in Dubai, and is recognized for its Centers of Excellence in specialties such as orthopedics, spine care, women’s health, and pediatrics.

With a strong focus on innovation, quality care, and sustainability, Medcare continues to expand its services and strengthen its presence in the UAE. This growth ensures access to comprehensive, specialized healthcare services aimed at improving the health and well-being of the community.

All Medcare hospitals are accredited by the US-based Joint Commission International (JCI), a non-profit organization focusing on healthcare quality and patient safety and is widely regarded as the gold standard for healthcare accreditation worldwide.

Dr. Shanila Laiju, group CEO of Medcare, began her career in 1994 as a dentist before transitioning into hospital administration. Over the years, she has progressed through various roles, including clinic supervisor, operations manager, group COO, and ultimately, group CEO.

With over two decades of experience, Dr. Laiju has been instrumental in driving Medcare’s success, motivating teams, and enhancing performance through a people-centric approach to management. Known for her hands-on leadership style, strategic decision-making, and financial discipline, she has cultivated a diverse and disciplined workforce, earned the trust of physicians, and fostered strong patient loyalty. Dr. Laiju is highly respected in the broader medical community for her effective communication skills and ability to build lasting relationships.

Dr. Laiju has led key initiatives in organizational planning, expansion, contract negotiations, and team development. She has also played a crucial role in increasing Medcare’s brand visibility and accelerating its growth. As a member of Aster DM Group’s Senior Management Committee, she has made a significant impact on the organization’s future direction.

A key highlight of Dr. Laiju’s leadership was her pivotal role in establishing Medcare’s Centers of Excellence, including the 65-bed Medcare Orthopedics & Spine Hospital and the 88-bed Medcare Women & Children Hospital. Her unwavering commitment to sustainability is reflected in various initiatives, such as reducing electricity and water consumption, promoting recycling, managing e-waste responsibly, and implementing electronic medical records to improve patient care and minimize paper use.

In the realm of corporate social responsibility (CSR), Dr. Laiju led a strategic partnership with the Palestine Children’s Relief Fund (PCRF) to provide free medical treatment to injured children in conflict zones across the Middle East.

Julphar is one of the largest pharmaceutical companies in the MEA region and one of the leading producers of insulin in the world.

Established in 1980, Julphar is known for manufacturing high quality, innovative and affordable medicines for families across the region and around the world.

Its core operations include general medicines in the retail pharmacy channel and hospitals as well as specialty products. Julphar’s medicines target major therapeutic segments including diabetes, gastrointestinal tract (GIT), respiratory, pain management, wounds and scars, anti-infectives, anemia, gynecology, dermatology, erectile dysfunction and cardiology.

The RAK-based manufacturer employs around 3,400 staff and markets products to more than 30 countries in five continents. Julphar’s 12 internationally accredited manufacturing facilities can produce up to 500,000 boxes of medicines daily. Julphar’s remarkable achievement happened in 2012, when the company became one of the world’s biggest producers of insulin, driven by its groundbreaking facilities in the UAE.

Leading the organization is Sheikh Saqer Bin Humaid Al Qassimi, a member of the Board of Directors of Julphar since 2005. Sheikh Saqer’s wide range of experience in sectors such as equities, commodity, currencies market, private equity management and his knowledge in logistics, education, healthcare, real estate, real estate management and F&B have been crucial in elevating Julphar’s status as a world leader in medicine manufacturing. He earned his Bachelor’s Degree in Finance from California State University.

“We understand that our role in the healthcare sector is not just about producing top-quality, cost-effective generic medications that benefit our customers. It also revolves around building an organization that is sustainable and socially responsible,” Sheikh Saqer said on his ESG report to the company.

Juphar’s Strategy 2030 lays out the organization’s path to strategic sustainable growth and is founded on six pillars: Maximizing revenue from current product portfolio; new product launches; geographical expansions; strategic business initiatives; advanced specialty products initiative; and inorganic growth initiatives.

American Hospital Dubai, a leading private healthcare provider in the region and part of the Mohamed & Obaid Al Mulla Group, was founded in 1996 with the mission of delivering world-class medical services to the community. The 254-bed, acute care hospital offers comprehensive medical and surgical care, equipped with state-of-the-art facilities and a skilled team of professionals from all over the world, specializing in over 40 medical and surgical specialties. All physicians at American Hospital are American Board Certified or hold equivalent credentials, ensuring that patients receive an internationally recognized standard of care in the UAE.

American Hospital Dubai was the first in the Middle East to receive Joint Commission International (JCI) accreditation, and its laboratory is the region’s first private sector facility accredited by the College of American Pathologists. The hospital is also a founding member of the prestigious Mayo Care Network. Furthermore, American Hospital was the first to offer a comprehensive one-stop cancer care program in Dubai and is home to the first American Heart Association (AHA) International Training Center for Life Support in a private UAE hospital.

To maintain the highest standards of care, American Hospital has implemented the Service Excellence Programme, and its Clinical Education Department offers multidisciplinary training for clinical staff. Additionally, the hospital has earned ultrasound practice accreditation from the Ultrasound Practice Accreditation Council of the American Institute of Ultrasound in Medicine (AIUM) in Abdomen/General, Breast – Diagnostic, and Breast – Interventional, making it the only facility outside the USA to receive this recognition.

In line with its commitment to innovation, American Hospital was the first in Dubai to introduce the fourth generation of the da Vinci Xi surgical system for robotic surgery, further establishing the city as a regional hub for medical tourism. As the first facility in Dubai to perform robotic surgeries, American Hospital is a pioneer in digital transformation within healthcare.

American Hospital also operates seven specialized clinics across Dubai – in Dubai Media City, Al Barsha, Al Khawaneej, Jumeirah, Mira, Dubai Hills, and Nad Al Sheba – bringing high-quality healthcare closer to the community.

Group CEO Sherif Beshara is a seasoned leader with extensive experience in the legal and corporate sectors. Holding a Master’s Degree in International Law, his career spans over a decade, with roles including legal counsel, chairman, and most recently, group CEO of the Mohamed & Obaid AlMulla Group of Companies. His expertise encompasses finance, aviation, and corporate law, advising top executives on airline matters, major joint ventures, and complex litigation.

Appointed by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, Beshara serves on the Board of Trustees of the Noor Foundation, an organization committed to eliminating the causes of visual impairment worldwide.

As group CEO, Beshara leads the Mohamed & Obaid AlMulla Group’s diverse portfolio, driving transformation and overseeing the group’s internal audit, corporate compliance programs, and policy formulation as part of the executive management team.

“American Hospital Dubai is committed to providing advanced medical technologies and collaborating with global experts in life sciences. It reflects our dedication to innovation, cutting-edge, multi-speciality healthcare services, and our commitment to patient safety and satisfaction,” he said.

in August 2024, American Hospital Dubai announced the opening of three medical tourism representative offices in Nigeria, as part of its broader plan to establish 30 offices across key African and Eastern European locations. This initiative supports the UAE’s ambition to become a global hub for medical tourism.

Dr. Sulaiman Al Habib Medical Services Group (HMG) is a leading force in the Middle East’s healthcare and solutions landscape, renowned for its comprehensive medical services, innovative approach, and exceptional patient care experience.

Boasting a dedicated team of over 3,500 physicians and 17,000 staff, HMG stands at the forefront of healthcare excellence. The group offers a wide range of services across more than 60 medical sub-specialties and operates an extensive network of over 1,370 clinics, making high-quality care readily available to communities throughout the region. With more than 1,900 beds, the group provides state-of-the-art facilities for patients, all supported by over 300 esteemed accreditations that ensure the highest standards of healthcare delivery. Robust infrastructure, combined with a team of highly skilled professionals, enables HMG to continue providing world-class healthcare services, solidifying its position as a leader in the industry.

Dr. Sulaiman Al Habib is the founder and chairman of the Board of Directors of both the Dr. Sulaiman Al Habib Medical Services Group and Dr. Sulaiman Al Habib Investment Company. He previously served as the Head of the Department of Pediatrics at the Security Forces Hospital in Riyadh from 1988 to 1991. Dr. Al Habib earned his Bachelor’s Degree in Medicine and Surgery from King Saud University’s College of Medicine in Riyadh in 1977. He also holds a fellowship in Pediatrics from the British Royal College of Physicians, awarded in 1984.

In its latest financial report, the Tadawul-listed hospital posted impressive numbers, with profits reaching SAR595.5 million ($158.75 million) in the third quarter of 2024, on the back of overall revenue growth of the hospitals and pharmacies segments.

Philips Healthcare is a global leader in health technology, specializing in innovative solutions that enhance patient care and improve health outcomes. As part of Royal Philips, a multinational conglomerate, Philips Healthcare focuses on providing a wide range of medical devices, imaging systems, and healthcare services aimed at transforming healthcare delivery. The company is known for its advancements in diagnostic imaging, including MRI, CT, ultrasound, and X-ray technologies, as well as monitoring, therapeutic devices, and healthcare informatics solutions.

Philips Healthcare emphasizes the integration of cutting-edge technologies, such as AI and data analytics, to enable more accurate diagnostics, personalized treatments, and streamlined healthcare workflows. The company’s solutions support healthcare providers in delivering high-quality care across various settings, from hospitals to home care environments. Through its focus on innovation, sustainability, and improving patient experiences, Philips Healthcare aims to address some of the most pressing challenges in global healthcare and create a healthier future for people in the region and around the world.

Vincenzo Ventricelli, CEO of Philips Middle East, Turkey and Africa, is a passionate business leader with a proven track record in building profitable businesses and driving growth. With a strong ability to lead and inspire teams, he ensures the successful execution of both short- and long-term business priorities. He brings over 20 years of experience in B2C and B2B business management, marketing, and sales across the Middle East and Europe.

He graduated in Business Administration from Bocconi University in Italy, laying the foundation for his successful career. He began his professional journey at Philips in 1996 as a Product Manager. Over the next eight years, he worked in Italy, taking on various marketing roles from 1996 to 2000, and later transitioning into sales management from 2000 to 2004.

In 2004, Ventricelli moved to Vienna, Austria, where he returned to a marketing role. By 2006, he was appointed marketing director for Central and Eastern Europe, expanding his leadership scope across multiple regions.

In 2008, his career took him to the Middle East, where he became marketing director for Philips Consumer Lifestyle Middle East & Africa, based in Dubai. In 2011, he transitioned back to sales, taking on the role of senior sales director for the Middle East and Turkey, using his marketing expertise to drive impactful sales strategies.

In February of last year, Royal Philips, the parent company of Philips Healthcare, announced a groundbreaking collaboration with Malaffi, the region’s first Health Information Exchange (HIE) platform, operated by Abu Dhabi Health Data Services and a strategic initiative of the Department of Health – Abu Dhabi (DoH). The partnership was formalized with an agreement signed during last year’s Arab Health, marking Malaffi’s official recognition as a global reference site for Philips’ Image Exchange Solution.

On the ESG side, Philips is building on its strong heritage in environmental sustainability and social impact and has adopted a fully integrated approach to doing business responsibly and sustainably. The group is partnering with stakeholders to drive environmental, social and governance (ESG) priorities and make a global impact. Philips aims to improve the lives of 2.5 billion people annually, including 400 million in underserved communities by 2030 and is making efforts to increase circular revenues from 15 percent of sales in 2020 to 25 percent of sales by 2025.

Dr. Zulekha Daud is widely recognized as the first Indian female medical professional to practice in the UAE. Arriving in the region in the 1960s, when healthcare access was limited, she dedicated herself to improving the welfare of both Emiratis and expatriates. Over the past five decades, Dr. Daud has not only transformed the healthcare landscape but also inspired countless others to follow in her footsteps. Today, Zulekha Healthcare Group stands as a leading force in the region, with state-of-the-art specialty hospitals, medical centers, educational institutions, and pharmacies across the UAE and India.

Dr. Daud earned her medical degree from the Government Medical College in Nagpur before moving to the UAE in 1964 to join the Kuwaiti Mission Hospital in Sharjah, a time when female doctors were scarce in the region. After years of devoted service, she founded Zulekha Hospital in Sharjah in 1992. What started as a modest 30-bed hospital offering basic services in gynecology, obstetrics, surgery, general medicine, and pediatrics, has since grown into a beacon of healthcare excellence.

Today, Zulekha Healthcare Group encompasses two multidisciplinary hospitals in Dubai and Sharjah, three medical centers, and three pharmacies. The group provides specialized care in over 30 medical disciplines and has expanded its reach to India, with the establishment of a multidisciplinary hospital in Nagpur, Central India. Through her vision and relentless commitment, Dr. Daud has revolutionized healthcare delivery, leaving a lasting impact on the region and beyond.

In recognition of her outstanding contributions, Dr. Daud was honored with the Dubai Quality Appreciation Award by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai.